,

Alexandra E Rojek1, Benjamin J McCormick2, Joanna Cwykiel3

  • 1Department of Medicine Section of Hematology/Oncology University of Chicago Chicago Illinois USA.

EJHaem
|August 19, 2024
PubMed
概括

加入密集化疗 (IC) 的gemtuzumab ozogamicin (GO) 并没有改善核心结合因子急性髓性白血病 (CBF-AML) 患者的结果. 然而,IC与KIT抑制剂相结合,在CBF-AML中显著提高了无事件生存率.